missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Serpin A3/alpha 1-Antichymotrypsin Antibody, Novus Biologicals™
Rabbit Polyclonal Antibody has been used in 2 publications
Brand: Novus Biologicals NBP1-90295
This item is not returnable.
View return policy
Description
Serpin A3/alpha 1-Antichymotrypsin Polyclonal specifically detects Serpin A3/alpha 1-Antichymotrypsin in Human samples. It is validated for Western Blot, Immunohistochemistry, Immunohistochemistry-Paraffin.
Specifications
| Serpin A3/alpha 1-Antichymotrypsin | |
| Polyclonal | |
| Western Blot 0.4 ug/ml, Immunohistochemistry 1:1000 - 1:2500, Immunohistochemistry-Paraffin 1:1000 - 1:2500 | |
| P01011 | |
| SERPINA3 | |
| This antibody was developed against Recombinant Protein corresponding to amino acids:QDKMEEVEAMLLPETLKRWRDSLEFREIGELYLPKFSISRDYNLNDILLQLGIEEAFTSKADLSGITGARNLAVSQVVHKAVLDVFEEGTEASAATAVKITLLSALVETRTIVRFNRPFLMIIVPTDTQNIFFMSKVTNPKQEGAPHR | |
| 0.1 mL | |
| Breast Cancer, Cancer | |
| 12 | |
| Human | |
| IgG |
| Western Blot, Immunohistochemistry, Immunohistochemistry (Paraffin) | |
| Unconjugated | |
| PBS (pH 7.2) and 40% Glycerol with 0.02% Sodium Azide | |
| AACTMGC88254, ACTGIG25, alpha-1-antichymotrypsin, antitrypsin), member 3, Cell growth-inhibiting gene 24/25 protein, growth-inhibiting protein 24, growth-inhibiting protein 25, member 3, serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, serine (or cysteine) proteinase inhibitor, clade A, member 3, Serpin A3, serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin) | |
| Rabbit | |
| Affinity Purified | |
| RUO | |
| Primary | |
| Specificity of antibody verified on a Protein Array containing target protein plus 383 other non-specific proteins. | |
| Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction